Silo Pharma, Inc. (SILO) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+443.7%

$6.58

vs $1.21 price

Levered DCF

$6.54

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

-6

Distress zone

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-0.68×	-0.75×	-1.2×	-1.96×	5.42×	-7.45×	-14.11×	-17.68×
P/B	0.45×	0.65×	0.72×	0.74×	1.5×	18.02×	-643.9×	42.18×
P/S	39.53×	45.43×	61.51×	106.45×	190.36×	0×	363.34×	0×
EV / EBITDA	0.45×	0.14×	-0.25×	0.95×	0.89×	-9.17×	-15.46×	-17.72×
Gross margin	-1128.9%	91.9%	91.9%	91.9%	93.0%	0.0%	32.5%	0.0%
Operating margin	-5937.0%	-6526.4%	-5347.4%	-5031.3%	-3851.0%	0.0%	-2293.4%	0.0%
Net margin	-5863.5%	-6092.6%	-5132.6%	-5420.9%	5477.9%	0.0%	-2497.7%	0.0%
Current ratio	11.36×	4.29×	9.9×	26.52×	21.23×	10.07×	4.23×	13.05×
Debt / equity	0×	0×	0×	0×	0×	0.01×	-2.7×	0.05×
Interest coverage	-114.76×	-925.59×	-791.87×	-1,649.68×	-903.93×	-8.18×	-14.79×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-67.0%	-87.3%	-59.9%	-37.8%	43.1%	-237.2%	4426.4%	-237.9%
Return on invested capital	-61.5%	-81.8%	-55.3%	-32.4%	-27.3%	-169.4%	-211.9%	-71.6%
Return on assets	-55.6%	-59.3%	-47.8%	-33.6%	37.2%	-212.9%	-205.2%	-113.3%
Free cash flow yield	-163.6%	-117.0%	-72.7%	-45.6%	-16.8%	-5.0%	-5.4%	1.6%
Earnings yield	-148.3%	-134.1%	-83.4%	-50.9%	28.8%	-13.2%	-6.9%	-5.6%
Enterprise value	-$1.9M	-$630.3K	$910.7K	-$3.7M	$3.7M	$22M	$14.7M	$16.9M
Net debt / EBITDA	1.14×	0.89×	0.97×	2.91×	-2.35×	0.46×	0.05×	0.33×
Cash conversion cycle (days)	-238	-99,027	-43,983	-22,437	-30,485	0	3,152	28